Buy GLP-3 Retatrutide – Peptide Partners

Product Overview & Specifications

GLP-3 Retatrutide is a research peptide investigated as a unimolecular agonist at the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). Peptide Partners supplies this compound for in-vitro testing, laboratory experimentation, receptor pharmacology, structural biology, and preclinical research.

Published studies have examined retatrutide using cryogenic electron microscopy, receptor mutagenesis, cAMP signaling assays, primary human hepatocytes, clinical-study samples, and preclinical models. Research areas include triple-receptor binding, receptor-specific contacts, ANGPTL3/8 secretion, serum-lipid relationships, and experimental metabolic signaling.

The product name supplied for this listing is “GLP-3 Retatrutide.” Researchers should verify the exact identity, sequence, formulation, and batch-specific certificate of analysis before beginning any experiment. Findings from published retatrutide studies should not be assumed to apply to every commercial batch or formulation.

Product Specifications

Specification	Details
Product name	GLP-3 Retatrutide
Compound type	Triple GLP-1R, GIPR, and GCGR agonist research peptide
Primary molecular targets	GLP-1 receptor, GIP receptor, and glucagon receptor
Primary research areas	Triple-receptor pharmacology, structural biology, cAMP signaling, hepatocyte research, and preclinical metabolism
Product format	24 mg vials
Vial size	24 mg
Vial capacity	3 mL
Available box combinations	48 mg, 120 mg, 240 mg, and 480 mg
Multi-vial purity	99.76%
Independent testing	Yes
Endotoxin screening	Passed
Heavy-metals screening	Passed
Purity screening	Passed
Manufacturer ID	WF03
Batch ID	RT202607
Cost per milligram	$3.15–$4.79

The stated 99.76% purity is based on multi-vial testing. Researchers should review the batch-specific certificate of analysis before beginning any experiment.

Primary Research Studies & Findings

Structural Insights Into the Triple Agonism at GLP-1R, GIPR, and GCGR Manifested by Retatrutide

Authors: Wenzhuo Li, Qingtong Zhou, Zhaotong Cong, Qingning Yuan, Wenxin Li, Fenghui Zhao, H. Eric Xu, Li-Hua Zhao, Dehua Yang, and Ming-Wei Wang

Publication: Cell Discovery, 2024;10:77

DOI: 10.1038/s41421-024-00700-0

Reference: View publication

This study used single-particle cryogenic electron microscopy to determine structures of retatrutide bound to GLP-1R, GIPR, and GCGR in complex with G_s proteins. The reported structures had overall resolutions of approximately 2.68 Å for GLP-1R, 3.26 Å for GIPR, and 2.84 Å for GCGR.

The researchers reported that retatrutide adopts a continuous helical conformation and uses a combination of conserved receptor contacts and receptor-specific interactions. Differences in extracellular loops, transmembrane regions, and receptor-specific residues were associated with distinct binding arrangements at the three receptors.

Mutagenesis and cAMP-signaling experiments were used to evaluate the functional importance of selected receptor–peptide contacts. The study identified extracellular loop 1 of GIPR and several conserved or receptor-specific residues as important contributors to retatrutide activity in the tested systems.

Plain-English Research Summary

This study created detailed structural models showing how retatrutide interacts with three receptor types. The researchers found that the peptide uses shared contact points while adapting to features unique to each receptor. The findings clarify receptor pharmacology in laboratory systems and do not establish clinical effectiveness for the supplied research material.

Decreases in Circulating ANGPTL3/8 Concentrations Following Retatrutide Treatment Parallel Reductions in Serum Lipids

Authors: Yi Wen, Deven Lemen, Yanzhu Lin, Yan Q. Chen, Ajit Regmi, William C. Roell, Melissa K. Thomas, Mark L. Hartman, Tamer Coskun, Zvonko Milicevic, Axel Haupt, Giacomo Ruotolo, and Robert J. Konrad

Publication: Diabetes, Obesity and Metabolism, 2025;27(10):5985–5995

DOI: 10.1111/dom.16661

Reference: PubMed 40726454

This study combined post-hoc analyses from two phase 2 clinical trials with in-vitro experiments using primary human hepatocytes. The researchers measured circulating ANGPTL3/8 and related proteins and examined associations with triglycerides, LDL cholesterol, and other metabolic parameters.

In the hepatocyte experiments, retatrutide and glucagon reduced ANGPTL3/8 secretion. The response was blocked by a glucagon-receptor antagonist, supporting a role for GCGR signaling in the observed effect. In the clinical-study analyses, reductions in ANGPTL3/8 were reported alongside reductions in triglycerides and LDL cholesterol.

The hepatocyte findings provide a mechanistic laboratory context, while the clinical analyses are separate from testing of the supplied research vial. Correlation between ANGPTL3/8 and lipid changes does not by itself establish a direct causal relationship for every setting.

Plain-English Research Summary

This study examined whether retatrutide affects a liver-derived protein complex involved in lipid metabolism. In cultured human liver cells, the researchers observed reduced ANGPTL3/8 secretion through a pathway involving the glucagon receptor. The findings combine cell experiments and clinical-study analyses and should not be presented as a human-use claim for this product.

Pharmacological Dissection Identifies Retatrutide Overcomes the Therapeutic Barrier of Obese TNBC Treatments Through Suppressing the Interplay Between Glycosylation and Ubiquitylation of YAP

Authors: Xin Cui, Yueming Zhu, Lidan Zeng, Mengyuan Zhang, Amad Uddin, Theresa W. Gillespie, Lauren E. McCullough, Shaying Zhao, Mylin A. Torres, and Yong Wan

Publication source: 2025

Reference: PubMed 39868848

This study investigated retatrutide in experimental models of obesity-associated triple-negative breast cancer. The researchers examined interactions between cancer-associated adipocytes, the hexosamine biosynthetic pathway, YAP protein regulation, glycosylation, ubiquitylation, tumor-cell behavior, and chemotherapy response.

The reported in-vitro findings associated cancer-associated adipocytes with increased O-GlcNAcylation and stabilization of YAP. Retatrutide was reported to suppress aspects of this metabolic pathway, promote YAP degradation, and alter tumor-cell responses in the tested models.

The study concerns experimental cancer biology and does not establish that retatrutide treats cancer, improves chemotherapy, or produces the same effects in humans. The findings should be presented only as an area of preclinical investigation.

Plain-English Research Summary

This research examined how metabolic signals from nearby fat cells may influence cancer-cell behavior in laboratory models. The researchers studied whether retatrutide altered a pathway involving O-GlcNAcylation and the YAP protein. The results are exploratory and preclinical and do not establish a cancer-treatment effect.

Standard Research Disclaimer

Research Use Only. Not for use in diagnostic tests.

This product is solely intended for research purposes as a chemical compound. It is designated exclusively for in-vitro testing and laboratory experimentation. All information provided about this product is educational and should be evaluated by appropriately qualified research personnel.

By law, bodily introduction of this product into humans or animals is strictly prohibited. This compound must not be used, administered, or represented as a drug, food, dietary supplement, weight-management product, lipid-lowering product, cancer treatment, diagnostic material, or medical treatment. It is not intended to diagnose, treat, cure, or prevent any disease. It should be handled only by licensed and qualified professionals in an appropriately equipped laboratory and in accordance with applicable laws, institutional procedures, and relevant safety requirements.